{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:08:30Z","timestamp":1783897710508,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL169517"],"award-info":[{"award-number":["1R01HL169517"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32 HL1605"],"award-info":[{"award-number":["T32 HL1605"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Echo Res Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Reported adverse events (AEs) to the Food and Drug Administration Adverse Event Reporting System (FAERS) have suggested an increased rate of serious AEs (SAEs) during the COVID-19 pandemic, but the extent to which this may be related to overall changes in reporting during this time period is uncertain. Accordingly, we aimed to evaluate trends in SAE reporting across commercially available ultrasound enhancing agent (UEA) brands as a function of overall trends in AE reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the FAERS public database, 2014\u20132024, to evaluate risks of UEAs overall and by brand, compared to similar contrast media.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2014 and 2024, 21,960,760 AEs were reported to FAERS, of which 11,450,891 (52.1%) were categorized as SAEs. Overall SAE reports to FAERS increased from 678,953 in 2014 to 1,368,393 in 2021 before subsequently declining to 1,065,845 in 2024 (-7.9% change from 2021 to 2024). During the same period, overall death reports to FAERS increased from 124,055 in 2014 to 195,207 in 2018 before declining to 147,046 in 2024. During this period of decline, there was a 23.9% relative increase in SAEs to UEAs which peaked in 2023 at 350 before declining to 326 in 2024. Deaths attributed to SAEs increased from 1 in 2014 to 19 in 2023 before declining to 9 in 2024. Overall, these data suggest that 11.2% of the observed increase in SAEs to UEAs can be attributed to reporting changes. Despite changes in relative risks for SAEs, absolute SAE rates remained small and lower than other types of contrast media.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this analysis of the FAERS dataset, 2014\u20132024, 11.2% of SAEs to UEAs were attributable to temporal changes in AE reporting. Absolute risks are small and declining, suggesting broad safety of UEAs as a class. Collectively, these results support continued use of UEAs, but motivate improved safety screening and preparedness to mitigate small but existing risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s44156-026-00127-1","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:01:11Z","timestamp":1783897271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reported safety events from ultrasound enhancing agents: a critical reappraisal"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6592-6141","authenticated-orcid":false,"given":"Jordan B.","family":"Strom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Spetko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance E. M.","family":"Angell-James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline A.","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Stout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan L.","family":"Winburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alecia","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateshwar","family":"Polsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Cosby A.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"127_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/HCO.0000000000000973","volume":"37","author":"AM Fraiche","year":"2022","unstructured":"Fraiche AM, Strom JB. Impact of ultrasound enhancing agents on clinical management. Curr Opin Cardiol. 2022;37:389\u201393.","journal-title":"Curr Opin Cardiol"},{"key":"127_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.echo.2017.11.013","volume":"31","author":"TR Porter","year":"2018","unstructured":"Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et al. Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update. J Am Soc Echocardiogr. 2018;31:241\u201374.","journal-title":"J Am Soc Echocardiogr"},{"key":"127_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.yacr.2020.06.004","volume":"2","author":"SR Wilson","year":"2020","unstructured":"Wilson SR, Barr RG. Contrast-Enhanced Ultrasonography of the Abdomen: Ready for Prime Time! Adv Clin Radiol. 2020;2:213\u201333.","journal-title":"Adv Clin Radiol"},{"key":"127_CR4","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s00261-017-1315-0","volume":"43","author":"A Ntoulia","year":"2018","unstructured":"Ntoulia A, Anupindi SA, Darge K, Back SJ. Applications of contrast-enhanced ultrasound in the pediatric abdomen. Abdom Radiol. 2018;43:948\u201359.","journal-title":"Abdom Radiol"},{"key":"127_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/ejechocard\/jep102","volume":"10","author":"S Kaul","year":"2009","unstructured":"Kaul S, Wei K. When you have eliminated the impossible, whatever remains, however improbable, must be the truth. Eur J Echocardiogr. 2009;10:713\u20135.","journal-title":"Eur J Echocardiogr"},{"key":"127_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jcmg.2013.08.012","volume":"7","author":"ML Main","year":"2014","unstructured":"Main ML, Hibberd MG, Ryan A, Lowe TJ, Miller P, Bhat G. Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent. JACC Cardiovasc Imaging. 2014;7:40\u20138.","journal-title":"JACC Cardiovasc Imaging"},{"key":"127_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jcmg.2010.04.006","volume":"3","author":"A Exuzides","year":"2010","unstructured":"Exuzides A, Main ML, Colby C, Grayburn PA, Feinstein SB, Goldman JH. A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent. JACC Cardiovasc Imaging. 2010;3:578\u201385.","journal-title":"JACC Cardiovasc Imaging"},{"key":"127_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","volume":"216","author":"J Szebeni","year":"2005","unstructured":"Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216:106\u201321.","journal-title":"Toxicology"},{"key":"127_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.echo.2021.09.014","volume":"35","author":"M Soni","year":"2022","unstructured":"Soni M, McGovern M, Jacob R, Weiss R, Adusumalli S, Litwin S, et al. Ultrasound-Enhancing Agents and Associated Adverse Reactions: A Potential Connection to the COVID-19 Vaccines? J Am Soc Echocardiogr. 2022;35:241\u20132.","journal-title":"J Am Soc Echocardiogr"},{"key":"127_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.echo.2022.02.006","volume":"35","author":"AK Desai","year":"2022","unstructured":"Desai AK, Hodovan J, Belcik JT, Lindner JR. Hypersensitivity Cross-Reactivity for Ultrasound-Enhancing Agents and COVID-19 Vaccines. J Am Soc Echocardiogr. 2022;35:523\u20135.","journal-title":"J Am Soc Echocardiogr"},{"key":"127_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.echo.2023.10.010","volume":"37","author":"MT Ali","year":"2024","unstructured":"Ali MT, Johnson M, Irwin T, Henry S, Sugeng L, Kansal S, et al. Incidence of Severe Adverse Drug Reactions to Ultrasound Enhancement Agents in a Contemporary Echocardiography Practice. J J Am Soc Echocardiogr. 2024;37:276\u201384.","journal-title":"J J Am Soc Echocardiogr"},{"key":"127_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.amjcard.2024.11.009","volume":"237","author":"RDLF Gonzalez","year":"2025","unstructured":"Gonzalez RDLF, Cabra A, Liu D, Gueco M, Naslazi E, Fu S, et al. Comparative Safety of Ultrasound Enhancing Agents: A Systematic Review and Bayesian Network Meta-Analysis: Comparative Safety Evaluation of Optison. Am J Cardiol. 2025;237:6\u201313.","journal-title":"Am J Cardiol"},{"key":"127_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.amjcard.2024.11.035","volume":"239","author":"JB Strom","year":"2025","unstructured":"Strom JB, Mulvagh SL, Porter TR, Main ML, Grayburn PA. Illuminating the Safety of Ultrasound Contrast Agents. Am J Cardiol. 2025;239:95\u20137.","journal-title":"Am J Cardiol"},{"key":"127_CR14","doi-asserted-by":"publisher","first-page":"e039480","DOI":"10.1161\/JAHA.124.039480","volume":"14","author":"JB Strom","year":"2025","unstructured":"Strom JB, Mulvagh SL, Porter TR, Wei K, Stout JL, Main ML. Contemporary Safety of Ultrasound Enhancing Agents in a Nationwide Analysis. J Am Heart Assoc. 2025;14:e039480.","journal-title":"J Am Heart Assoc"},{"key":"127_CR15","unstructured":"US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. 2024. https:\/\/www.fda.gov\/drugs\/fda-adverse-event-monitoring-system-aems\/fda-adverse-event-monitoring-system-aems-public-dashboard. Accessed 29 May 2026."},{"key":"127_CR16","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jacc.2008.03.006","volume":"51","author":"LL Kusnetzky","year":"2008","unstructured":"Kusnetzky LL, Khalid A, Khumri TM, Moe TG, Jones PG, Main ML. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies. J Am Coll Cardiol. 2008;51:1704\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"127_CR17","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jcmg.2009.03.020","volume":"2","author":"SS Abdelmoneim","year":"2009","unstructured":"Abdelmoneim SS, Bernier M, Scott CG, Dhoble A, Ness SA, Hagen ME, et al. Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients. JACC Cardiovasc Imaging. 2009;2:1048\u201356.","journal-title":"JACC Cardiovasc Imaging"},{"key":"127_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.amjcard.2008.06.066","volume":"102","author":"RS Gabriel","year":"2008","unstructured":"Gabriel RS, Smyth YM, Menon V, Klein AL, Grimm RA, Thomas JD, et al. Safety of Ultrasound Contrast Agents in Stress Echocardiography. Am J Cardiol. 2008;102:1269\u201372.","journal-title":"Am J Cardiol"},{"key":"127_CR19","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.amjcard.2008.07.032","volume":"102","author":"K Shaikh","year":"2008","unstructured":"Shaikh K, Chang SM, Peterson L, Rosendahl-Garcia K, Quinones MA, Nagueh SF, et al. Safety of Contrast Administration for Endocardial Enhancement During Stress Echocardiography Compared With Noncontrast Stress. Am J Cardiol. 2008;102:1444\u201350.","journal-title":"Am J Cardiol"},{"key":"127_CR20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.amjcard.2010.04.034","volume":"106","author":"OA Khawaja","year":"2010","unstructured":"Khawaja OA, Shaikh KA, Al-Mallah MH. Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents. Am J Cardiol. 2010;106:742\u20137.","journal-title":"Am J Cardiol"},{"key":"127_CR21","unstructured":"Intersocietal Accreditation Commission. IAC Standards & Guidelines for Adult Echocardiography Accreditation. 2025. https:\/\/intersocietal.org\/wp-content\/uploads\/2025\/08\/IACAdultEchocardiographyStandards2025.pdf. Accessed 29 May 2026."},{"key":"127_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s44156-024-00068-7","volume":"12","author":"JB Strom","year":"2025","unstructured":"Strom JB, Appis A, Barr RG, Chammas MC, Clevert D-A, Darge K, et al. Multi-societal expert consensus statement on the safe administration of ultrasound contrast agents. Echo Res Pract. 2025;12:4.","journal-title":"Echo Res Pract"},{"key":"127_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.echo.2014.05.011","volume":"27","author":"TR Porter","year":"2014","unstructured":"Porter TR, Abdelmoneim S, Belcik JT, McCulloch ML, Mulvagh SL, Olson JJ, et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography. J Am Soc Echocardiogr. 2014;27:797\u2013810.","journal-title":"J Am Soc Echocardiogr"},{"key":"127_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s44156-022-00008-3","volume":"9","author":"TR Porter","year":"2022","unstructured":"Porter TR, Feinstein SB, Senior R, Mulvagh SL, Nihoyannopoulos P, Strom JB, et al. CEUS cardiac exam protocols International Contrast Ultrasound Society (ICUS) recommendations. Echo Res Praxct. 2022;9:7.","journal-title":"Echo Res Praxct"},{"key":"127_CR25","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/j.bja.2020.12.020","volume":"126","author":"LH Garvey","year":"2021","unstructured":"Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesth. 2021;126:e106\u20138.","journal-title":"Br J Anaesth"},{"key":"127_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/cea.13874","volume":"51","author":"P Sellaturay","year":"2021","unstructured":"Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy. 2021;51:861\u20133.","journal-title":"Clin Exp Allergy"},{"key":"127_CR27","doi-asserted-by":"crossref","unstructured":"Krantz MS, Liu Y, Phillips EJ, Stone CA. Jr. Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy. J Allergy Clin Immunol Pract. 2020;8:1416-9.e3.","DOI":"10.1016\/j.jaip.2019.12.041"},{"key":"127_CR28","doi-asserted-by":"crossref","unstructured":"Stone CA Jr., Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019;7:1533-40.e8.","DOI":"10.1016\/j.jaip.2018.12.003"},{"key":"127_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/wnan.1339","volume":"7","author":"Q Yang","year":"2015","unstructured":"Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. WIREs Nanomed Nanobiotechnol. 2015;7:655\u201377.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"127_CR30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/cea.12760","volume":"46","author":"E Wenande","year":"2016","unstructured":"Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46:907\u201322.","journal-title":"Clin Exp Allergy"},{"key":"127_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000233512","volume":"74","author":"AW Richter","year":"2009","unstructured":"Richter AW, \u00c5kerblom E. Polyethylene Glycol Reactive Antibodies in Man: Titer Distribution in Allergic Patients Treated with Monomethoxy Polyethylene Glycol Modified Allergens or Placebo, and in Healthy Blood Donors. Int Arch Allergy Appl Immunol. 2009;74:36\u20139.","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"127_CR32","doi-asserted-by":"crossref","unstructured":"Zhou ZH, Stone CA Jr., Jakubovic B, Phillips EJ, Sussman G, Park J et al. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J Allergy Clin Immunol Pract. 2021;9:1731-3.e3.","DOI":"10.1016\/j.jaip.2020.11.011"},{"key":"127_CR33","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.jaip.2019.05.058","volume":"7","author":"G Calogiuri","year":"2019","unstructured":"Calogiuri G, Foti C, Nettis E, Di Leo E, Macchia L, Vacca A. Polyethylene glycols and polysorbates: Two still neglected ingredients causing true IgE-mediated reactions. J Allergy Clin Immunol Pract. 2019;7:2509\u201310.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"127_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cea.14064","volume":"52","author":"P Sellaturay","year":"2022","unstructured":"Sellaturay P, Gurugama P, Harper V, Dymond T, Ewan P, Nasser S. The Polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients. Clin Exp Allergy. 2022;52:12\u20137.","journal-title":"Clin Exp Allergy"},{"key":"127_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-publhealth-071723-102841","volume":"46","author":"E Fernandez","year":"2025","unstructured":"Fernandez E, Jaggers J, Norton AE, Stone C, Phillips E. Adverse Events Following Vaccines: From Detection to Research Translation. Annu Rev Public Health. 2025;46:1\u201319.","journal-title":"Annu Rev Public Health"},{"key":"127_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jaci.2023.05.019","volume":"152","author":"M Greenhawt","year":"2023","unstructured":"Greenhawt M, Dribin TE, Abrams EM, Shaker M, Chu DK, Golden DBK, et al. Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach. J Allergy Clin Immunol. 2023;152:309\u201325.","journal-title":"J Allergy Clin Immunol"},{"key":"127_CR37","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.jaip.2023.05.004","volume":"11","author":"CA Stone","year":"2023","unstructured":"Stone CA Jr., Garvey LH, Nasser S, Lever C, Triggiani M, Parente R, et al. Identifying and Managing Those at Risk for Vaccine-Related Allergy and Anaphylaxis. J Allergy Clin Immunol Pract. 2023;11:2008\u201322.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"127_CR38","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaip.2022.08.048","volume":"11","author":"CA Stone","year":"2023","unstructured":"Stone CA Jr., Robinson LB, Li L, Krantz MS, Kwah JH, Ortega G, et al. Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis. J Allergy Clin Immunol Pract. 2023;11:458\u201365.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"127_CR39","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1001\/jamainternmed.2021.3779","volume":"181","author":"MS Krantz","year":"2021","unstructured":"Krantz MS, Kwah JH, Stone CA Jr., Phillips EJ, Ortega G, Banerji A, et al. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Intern Med. 2021;181:1530\u20133.","journal-title":"JAMA Intern Med"},{"key":"127_CR40","first-page":"143","volume":"6","author":"NA Oyarzabal","year":"2017","unstructured":"Oyarzabal NA, Areso NL, Belar NB, Popolizio IG, Arregui AV, de Vallejo OVB. Anaphylactic shock due to allergy to macrogol 4000 contained in SonoVue\u00ae. Case Rep Clin Med. 2017;6:143\u20137.","journal-title":"Case Rep Clin Med"},{"key":"127_CR41","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaip.2020.09.029","volume":"9","author":"P Sellaturay","year":"2021","unstructured":"Sellaturay P, Nasser S, Ewan P. Polyethylene glycol\u2013induced systemic allergic reactions (anaphylaxis). J Allergy Clin Immunol Pract. 2021;9:670\u20135.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"127_CR42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.echo.2021.05.002","volume":"34","author":"JR Lindner","year":"2021","unstructured":"Lindner JR, Belcik T, Main ML, Montanaro A, Mulvagh SL, Olson J, et al. Expert Consensus Statement from the American Society of Echocardiography on Hypersensitivity Reactions to Ultrasound Enhancing Agents in Patients with Allergy to Polyethylene Glycol. J Am Soc Echocardiogr. 2021;34:707\u20138.","journal-title":"J Am Soc Echocardiogr"},{"key":"127_CR43","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.ultrasmedbio.2006.05.031","volume":"32","author":"F Piscaglia","year":"2006","unstructured":"Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol. 2006;32:1369\u201375.","journal-title":"Ultrasound Med Biol"},{"key":"127_CR44","doi-asserted-by":"publisher","first-page":"33184","DOI":"10.1038\/s41598-025-17777-6","volume":"15","author":"A Vojdani","year":"2025","unstructured":"Vojdani A, Vojdani E. Detection of PEG-specific antibodies in SARS-CoV-2 positive and negative sera with implications for autoimmune reactivity. Sci Rep. 2025;15:33184.","journal-title":"Sci Rep"},{"key":"127_CR45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jconrel.2024.01.003","volume":"366","author":"Z Li","year":"2024","unstructured":"Li Z, Ma A, Miller I, Starnes R, Talkington A, Stone CA, et al. Development of anti-PEG IgG\/IgM\/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy. J Control Release. 2024;366:342\u20138.","journal-title":"J Control Release"},{"key":"127_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154\u2013155","author":"Kozma","year":"2020","unstructured":"Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154\u2013155:163\u201375.","journal-title":"Adv Drug Deliv Rev"},{"key":"127_CR47","doi-asserted-by":"publisher","first-page":"18817","DOI":"10.1038\/s41598-023-46275-w","volume":"13","author":"D Montes-Grajales","year":"2023","unstructured":"Montes-Grajales D, Garcia-Serna R, Mestres J. Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events. Sci Rep. 2023;13:18817.","journal-title":"Sci Rep"}],"container-title":["Echo Research &amp; Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44156-026-00127-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44156-026-00127-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44156-026-00127-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:01:14Z","timestamp":1783897274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s44156-026-00127-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["127"],"URL":"https:\/\/doi.org\/10.1186\/s44156-026-00127-1","relation":{},"ISSN":["2055-0464"],"issn-type":[{"value":"2055-0464","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JBS reports research grants from the National Heart, Lung, and Blood Institute (1R01HL169517, 1R01HL173998), Edwards Lifesciences, EchoIQ, Anumana, Philips Healthcare, Viz.ai, EVERSANA Lifesciences; consulting for Bracco Diagnostics, Edwards Lifesciences, Philips Healthcare, General Electric Healthcare, and EVERSANA Lifesciences; clinical endpoint committee for Pfizer and Agitated Solutions, and is a member of the scientific advisory boards for Ultromics, HeartSciences, Bristol Myers Squibb, Alnyam, Ultrasight, and EchoIQ. CES reports research funding from AHRQ R01HS030234, NIAID U01AI181927, NIAID U01 AI184071 and a pilot award for chemotherapy allergy research from the Vanderbilt Ingram Cancer Center\/Chic Awearness. Funders played no role in any aspect of this manuscript.\u202f\u202fHe reports consulting for Larimar Therapeutics and Stallergenes-Greer, which had no role in this manuscript. All other authors report no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}